Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

IBG vs CRBP vs AGIO vs WVVI

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
IBG
Innovation Beverage Group Limited

Beverages - Alcoholic

Consumer DefensiveNASDAQ • AU
Market Cap$1M
5Y Perf.-98.3%
CRBP
Corbus Pharmaceuticals Holdings, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$136M
5Y Perf.-46.9%
AGIO
Agios Pharmaceuticals, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$1.64B
5Y Perf.-37.5%
WVVI
Willamette Valley Vineyards, Inc.

Beverages - Wineries & Distilleries

Consumer DefensiveNASDAQ • US
Market Cap$14M
5Y Perf.-15.5%

IBG vs CRBP vs AGIO vs WVVI — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
IBG logoIBG
CRBP logoCRBP
AGIO logoAGIO
WVVI logoWVVI
IndustryBeverages - AlcoholicBiotechnologyBiotechnologyBeverages - Wineries & Distilleries
Market Cap$1M$136M$1.64B$14M
Revenue (TTM)$8M$0.00$66M$37M
Net Income (TTM)$-6M$-79M$-423M$-1M
Gross Margin11.3%82.1%60.5%
Operating Margin-71.3%-7.2%-2.4%
Total Debt$184K$2M$62M$15.52B
Cash & Equiv.$620K$28M$89M$411M

IBG vs CRBP vs AGIO vs WVVILong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

IBG
CRBP
AGIO
WVVI
StockSep 24May 26Return
Innovation Beverage… (IBG)1001.7-98.3%
Corbus Pharmaceutic… (CRBP)10053.1-46.9%
Agios Pharmaceutica… (AGIO)10062.5-37.5%
Willamette Valley V… (WVVI)10084.5-15.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: IBG vs CRBP vs AGIO vs WVVI

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CRBP and AGIO are tied at the top with 2 categories each — the right choice depends on your priorities. Agios Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. WVVI also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
IBG
Innovation Beverage Group Limited
The Secondary Option

IBG lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: consumer defensive exposure
CRBP
Corbus Pharmaceuticals Holdings, Inc.
The Quality Compounder

CRBP carries the broadest edge in this set and is the clearest fit for quality and momentum.

  • 3.3% margin vs AGIO's -6.4%
  • +77.3% vs IBG's -95.8%
Best for: quality and momentum
AGIO
Agios Pharmaceuticals, Inc.
The Income Pick

AGIO is the #2 pick in this set and the best alternative if income & stability and growth exposure is your priority.

  • beta 1.12
  • Rev growth 48.0%, EPS growth -161.2%, 3Y rev CAGR 56.0%
  • -42.2% 10Y total return vs WVVI's -59.3%
  • Lower volatility, beta 1.12, Low D/E 5.2%, current ratio 11.46x
Best for: income & stability and growth exposure
WVVI
Willamette Valley Vineyards, Inc.
The Income Pick

WVVI is the clearest fit if your priority is dividends and efficiency.

  • 100.0% yield; 4-year raise streak; the other 3 pay no meaningful dividend
  • -1.1% ROA vs IBG's -124.5%, ROIC -2.6% vs -87.3%
Best for: dividends and efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthAGIO logoAGIO48.0% revenue growth vs WVVI's -100.0%
Quality / MarginsCRBP logoCRBP3.3% margin vs AGIO's -6.4%
Stability / SafetyAGIO logoAGIOBeta 1.12 vs CRBP's 1.36
DividendsWVVI logoWVVI100.0% yield; 4-year raise streak; the other 3 pay no meaningful dividend
Momentum (1Y)CRBP logoCRBP+77.3% vs IBG's -95.8%
Efficiency (ROA)WVVI logoWVVI-1.1% ROA vs IBG's -124.5%, ROIC -2.6% vs -87.3%

IBG vs CRBP vs AGIO vs WVVI — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

IBGInnovation Beverage Group Limited

Segment breakdown not available.

CRBPCorbus Pharmaceuticals Holdings, Inc.

Segment breakdown not available.

AGIOAgios Pharmaceuticals, Inc.
FY 2025
Product
100.0%$54M
WVVIWillamette Valley Vineyards, Inc.

Segment breakdown not available.

IBG vs CRBP vs AGIO vs WVVI — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLWVVILAGGINGCRBP

Income & Cash Flow (Last 12 Months)

WVVI leads this category, winning 3 of 6 comparable metrics.

AGIO and CRBP operate at a comparable scale, with $66M and $0 in trailing revenue. Profitability is closely matched — net margins range from -3.3% (WVVI) to -6.4% (AGIO). On growth, AGIO holds the edge at +137.7% YoY revenue growth, suggesting stronger near-term business momentum.

MetricIBG logoIBGInnovation Bevera…CRBP logoCRBPCorbus Pharmaceut…AGIO logoAGIOAgios Pharmaceuti…WVVI logoWVVIWillamette Valley…
RevenueTrailing 12 months$8M$0$66M$37M
EBITDAEarnings before interest/tax-$5M-$84M-$470M$2M
Net IncomeAfter-tax profit-$6M-$79M-$423M-$1M
Free Cash FlowCash after capex-$3M-$64M-$385M-$3M
Gross MarginGross profit ÷ Revenue+11.3%+82.1%+60.5%
Operating MarginEBIT ÷ Revenue-71.3%-7.2%-2.4%
Net MarginNet income ÷ Revenue-80.0%-6.4%-3.3%
FCF MarginFCF ÷ Revenue-37.0%-5.8%-8.5%
Rev. Growth (YoY)Latest quarter vs prior year-38.6%+137.7%-10.9%
EPS Growth (YoY)Latest quarter vs prior year+39.3%-60.3%-9.0%-94.1%
WVVI leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

WVVI leads this category, winning 2 of 3 comparable metrics.
MetricIBG logoIBGInnovation Bevera…CRBP logoCRBPCorbus Pharmaceut…AGIO logoAGIOAgios Pharmaceuti…WVVI logoWVVIWillamette Valley…
Market CapShares × price$1M$136M$1.6B$14M
Enterprise ValueMkt cap + debt − cash$966,549$109M$1.6B$15.1B
Trailing P/EPrice ÷ TTM EPS-0.54x-1.84x-3.87x-4.53x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue0.48x30.30x
Price / BookPrice ÷ Book value/share0.54x0.98x1.34x0.00x
Price / FCFMarket cap ÷ FCF
WVVI leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

WVVI leads this category, winning 5 of 9 comparable metrics.

WVVI delivers a -1.8% return on equity — every $100 of shareholder capital generates $-2 in annual profit, vs $-10 for IBG. CRBP carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to WVVI's 0.23x. On the Piotroski fundamental quality scale (0–9), IBG scores 3/9 vs WVVI's 1/9, reflecting mixed financial health.

MetricIBG logoIBGInnovation Bevera…CRBP logoCRBPCorbus Pharmaceut…AGIO logoAGIOAgios Pharmaceuti…WVVI logoWVVIWillamette Valley…
ROE (TTM)Return on equity-10.1%-65.8%-34.1%-1.8%
ROA (TTM)Return on assets-124.5%-57.9%-31.7%-1.1%
ROICReturn on invested capital-87.3%-51.4%-26.3%-2.6%
ROCEReturn on capital employed-155.2%-58.5%-33.8%-3.1%
Piotroski ScoreFundamental quality 0–93221
Debt / EquityFinancial leverage0.07x0.01x0.05x0.23x
Net DebtTotal debt minus cash-$435,590-$27M-$27M$15.1B
Cash & Equiv.Liquid assets$619,944$28M$89M$411M
Total DebtShort + long-term debt$184,354$2M$62M$15.5B
Interest CoverageEBIT ÷ Interest expense-13.53x-0.69x
WVVI leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

AGIO leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in AGIO five years ago would be worth $4,935 today (with dividends reinvested), compared to $116 for IBG. Over the past 12 months, CRBP leads with a +77.3% total return vs IBG's -95.8%. The 3-year compound annual growth rate (CAGR) favors AGIO at 2.7% vs IBG's -77.4% — a key indicator of consistent wealth creation.

MetricIBG logoIBGInnovation Bevera…CRBP logoCRBPCorbus Pharmaceut…AGIO logoAGIOAgios Pharmaceuti…WVVI logoWVVIWillamette Valley…
YTD ReturnYear-to-date-91.1%+38.1%+1.3%-8.6%
1-Year ReturnPast 12 months-95.8%+77.3%-2.4%-49.3%
3-Year ReturnCumulative with dividends-98.8%+7.3%+8.3%-51.0%
5-Year ReturnCumulative with dividends-98.8%-78.0%-50.7%-80.8%
10-Year ReturnCumulative with dividends-98.8%-85.4%-42.2%-59.3%
CAGR (3Y)Annualised 3-year return-77.4%+2.4%+2.7%-21.2%
AGIO leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — AGIO and WVVI each lead in 1 of 2 comparable metrics.

WVVI is the less volatile stock with a -0.25 beta — it tends to amplify market swings less than CRBP's 1.36 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AGIO currently trades 59.8% from its 52-week high vs IBG's 2.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricIBG logoIBGInnovation Bevera…CRBP logoCRBPCorbus Pharmaceut…AGIO logoAGIOAgios Pharmaceuti…WVVI logoWVVIWillamette Valley…
Beta (5Y)Sensitivity to S&P 5001.12x1.22x1.12x-0.27x
52-Week HighHighest price in past year$36.50$20.56$46.00$7.18
52-Week LowLowest price in past year$0.84$6.10$22.24$2.49
% of 52W HighCurrent price vs 52-week peak+2.3%+52.9%+59.8%+40.3%
RSI (14)Momentum oscillator 0–10033.865.341.953.5
Avg Volume (50D)Average daily shares traded790K262K1.0M3K
Evenly matched — AGIO and WVVI each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: CRBP as "Buy", AGIO as "Buy". Consensus price targets imply 370.5% upside for CRBP (target: $51) vs 37.1% for AGIO (target: $38). WVVI is the only dividend payer here at 100.00% yield — a key consideration for income-focused portfolios.

MetricIBG logoIBGInnovation Bevera…CRBP logoCRBPCorbus Pharmaceut…AGIO logoAGIOAgios Pharmaceuti…WVVI logoWVVIWillamette Valley…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$51.14$37.75
# AnalystsCovering analysts1429
Dividend YieldAnnual dividend ÷ price+100.0%
Dividend StreakConsecutive years of raises4
Dividend / ShareAnnual DPS$194.20
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

WVVI leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). AGIO leads in 1 (Total Returns). 1 tied.

Best OverallWillamette Valley Vineyards… (WVVI)Leads 3 of 6 categories
Loading custom metrics...

IBG vs CRBP vs AGIO vs WVVI: Key Questions Answered

8 questions · data-driven answers · updated daily

01

Is IBG or CRBP or AGIO or WVVI a better buy right now?

For growth investors, Agios Pharmaceuticals, Inc.

(AGIO) is the stronger pick with 48. 0% revenue growth year-over-year, versus -100. 0% for Willamette Valley Vineyards, Inc. (WVVI). Analysts rate Corbus Pharmaceuticals Holdings, Inc. (CRBP) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — IBG or CRBP or AGIO or WVVI?

Over the past 5 years, Agios Pharmaceuticals, Inc.

(AGIO) delivered a total return of -50. 7%, compared to -98. 8% for Innovation Beverage Group Limited (IBG). Over 10 years, the gap is even starker: AGIO returned -42. 2% versus IBG's -98. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — IBG or CRBP or AGIO or WVVI?

By beta (market sensitivity over 5 years), Willamette Valley Vineyards, Inc.

(WVVI) is the lower-risk stock at -0. 27β versus Corbus Pharmaceuticals Holdings, Inc. 's 1. 22β — meaning CRBP is approximately -557% more volatile than WVVI relative to the S&P 500. On balance sheet safety, Corbus Pharmaceuticals Holdings, Inc. (CRBP) carries a lower debt/equity ratio of 1% versus 23% for Willamette Valley Vineyards, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — IBG or CRBP or AGIO or WVVI?

By revenue growth (latest reported year), Agios Pharmaceuticals, Inc.

(AGIO) is pulling ahead at 48. 0% versus -100. 0% for Willamette Valley Vineyards, Inc. (WVVI). On earnings-per-share growth, the picture is similar: Innovation Beverage Group Limited grew EPS -16. 5% year-over-year, compared to -161. 2% for Agios Pharmaceuticals, Inc.. Over a 3-year CAGR, AGIO leads at 56. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — IBG or CRBP or AGIO or WVVI?

Corbus Pharmaceuticals Holdings, Inc.

(CRBP) is the more profitable company, earning 0. 0% net margin versus -764. 0% for Agios Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRBP leads at 0. 0% versus -873. 9% for AGIO. At the gross margin level — before operating expenses — AGIO leads at 78. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — IBG or CRBP or AGIO or WVVI?

In this comparison, WVVI (100.

0% yield) pays a dividend. IBG, CRBP, AGIO do not pay a meaningful dividend and should not be held primarily for income.

07

Is IBG or CRBP or AGIO or WVVI better for a retirement portfolio?

For long-horizon retirement investors, Willamette Valley Vineyards, Inc.

(WVVI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 27), 100. 0% yield). Both have compounded well over 10 years (WVVI: -58. 7%, CRBP: -85. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between IBG and CRBP and AGIO and WVVI?

These companies operate in different sectors (IBG (Consumer Defensive) and CRBP (Healthcare) and AGIO (Healthcare) and WVVI (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: IBG is a small-cap quality compounder stock; CRBP is a small-cap quality compounder stock; AGIO is a small-cap high-growth stock; WVVI is a small-cap income-oriented stock. WVVI pays a dividend while IBG, CRBP, AGIO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

IBG

Quality Business

  • Sector: Consumer Defensive
  • Market Cap > $100B
Run This Screen
Stocks Like

CRBP

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

AGIO

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 68%
  • Gross Margin > 49%
Run This Screen
Stocks Like

WVVI

Income & Dividend Stock

  • Sector: Consumer Defensive
  • Market Cap > $100B
  • Gross Margin > 36%
  • Dividend Yield > 40.0%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.